Compass Point raised its rating on DR Horton (NYSE: DHI ) from Sell to Neutral and raised its price target to $18.50. Compass Point commented, "After a full model update we are raising estimates and, coupled with the stock's relative underperformance in the post-QE3 trade, we now feel DHI should